Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is currently conducting a Phase 3 clinical trial titled A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease. The study aims to assess the effectiveness of subcutaneous teprotumumab compared to a placebo in reducing proptosis, a symptom of thyroid eye disease, over a 24-week period.
The trial is testing teprotumumab, a biological intervention administered via subcutaneous injection, against a placebo. The primary goal is to determine if teprotumumab can significantly reduce eye protrusion in affected patients.
This study is designed as a randomized, triple-masked, placebo-controlled trial with parallel groups. The primary purpose is treatment, ensuring that neither participants nor their care providers and investigators know who receives the actual treatment or placebo.
The study began on July 5, 2024, with its primary completion expected in the future. The latest update was submitted on June 25, 2025. These dates are crucial as they help track the study’s progress and anticipated milestones.
The outcome of this trial could significantly impact Amgen’s stock performance and investor sentiment, especially if the results demonstrate a clear benefit of teprotumumab over placebo. This could position Amgen favorably against competitors in the thyroid eye disease treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.